Novartis scraps US submission of tislelizumab as a monotherapy for non-small cell lung cancer.

A study by the National Institute of Ageing found that a new blood test can accurately predict the presence of beta-amyloid plaques in the brain.

AbbVie announces official recommended approval of it Rinvoq treatment for adults with active non-radiographic axial spondyloarthritis.

Hot off the press, we look at this week’s breaking news stories from the Biologics industry.

Clinical studies testing treatments for severe COVID-19 face major delays due to eligibility issues.

Two roadblocks to the successful application of treatments for tumourous tissues are heterogenous antigen expression and antigen loss. Bispecific CAR-T cells, capable of simultaneously binding to two different antigens via heavy chain-only domains, may present a solution.

Researchers from ETH Zurich demonstrate the promise of deep learning for predicting antigen specificity.

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our April Discussion Group addressing ‘Accelerating Antibody Engineering With AI/ML & Advanced Computational Tools and Technologies’ brought together an exclusive panel of key opinion leaders to address the market’s growth and future outlook.

As market leaders in the biologics field, there is no sign of demand for antibody-based therapies slowing down any time soon. With exclusive insights from the CRUK-AstraZeneca Antibody Alliance Laboratory, we look towards the future of antibody discovery and optimisation.

While membrane proteins are inherently unstable and challenging to work with, Salipro Biotech are focusing on the stabilisation of challenging protein targets for a variety of downstream applications. This Commentary article explores how Salipro’s platform technology enables new opportunities for drug development.